EMEA-002887-PIP01-20
Key facts
| Active substance |
Ribitol
|
| Therapeutic area |
Other
|
| Decision number |
P/0387/2021
|
| PIP number |
EMEA-002887-PIP01-20
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of limb-girdle muscular dystrophy
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
ML Bio Solutions, Inc.
E-mail: info@mlbiosolutions.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|